Dr. Infante Talks About BRAF Mutation Testing

Jeffrey R. Infante, MD
Published: Tuesday, Jun 07, 2011

Jeffrey Infante, MD, director of drug development at the Sarah Cannon Research Institute talks about BRAF mutation testing.

Dr. Infante says that there is a subset of melanoma patients (about half) that have the BRAF mutation. He adds it can be tested easily around the country by multiple labs. If it turns out that a patient has a genetic change that is a BRAF mutation, there are drugs that can help the patient. While the drugs aren't FDA approved yet, there are many trials ongoing where patients can get access to those drugs.
Jeffrey Infante, MD, director of drug development at the Sarah Cannon Research Institute talks about BRAF mutation testing.

Dr. Infante says that there is a subset of melanoma patients (about half) that have the BRAF mutation. He adds it can be tested easily around the country by multiple labs. If it turns out that a patient has a genetic change that is a BRAF mutation, there are drugs that can help the patient. While the drugs aren't FDA approved yet, there are many trials ongoing where patients can get access to those drugs.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x